April  16, 2010 (FinancialWire) — Generex Biotechnology Corp. (NASDAQ: GNBT) said John Muir Physician Network Clinical Research Center has agreed to participate in the United States Food and Drug Administration Expanded Access Treatment Investigational New Drug Program for the company's flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product. In September 2009, the FDA approved the treatment use of Generex Oral-lyn™ under the FDA's Treatment IND Program.

John Muir Physician Network Clinical Research Center is a top-rated and prestigious clinical research site. John Muir Physician Network Clinical Research Center is part of the John Muir Physician Network, which is comprised of John Muir Medical Group, a group of nearly 800 providers, and is a subsidiary of John Muir Health, a recognized leader in providing quality medical care in the San Francisco/Bay Area. John Muir Physician Network Clinical Research Center will be the first site in the State of California to participate in the Treatment IND.

John Muir Physician Network Clinical Research Center provides rapid enrollment, high data integrity, as well as compassionate and quality care to their research subjects. It has extensive primary research experience in diabetes mellitus and its complications and other endocrine metabolic disorders such as obesity.

Under the Expanded Access Treatment IND program, Generex Oral-lyn™ will be provided to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for the treatment of diabetes, and who are not eligible to participate in the company's ongoing global Phase III pivotal clinical trial.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[frlylrf] [biomedphrm] [cnfrncvntprsntn] [prsnttnsntt]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.